Credits: Canva
The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.
It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.
The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.
In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.
TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."
Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.
While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.
Credit: AI
India is set to launch its first indigenously developed vaccine against H5N1 bird flu virus in chickens on November 20, as new outbreaks have been emerging in different parts of the country.
Developed by scientists at ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD), the inactivated vaccine targets H5N1 Clade 2.3.2.1a, a strain that caused several bird flu outbreaks among chickens in India.
According to the Ministry of Agriculture and Farmers' Welfare, this marks a significant development in poultry and public health as there is no commercial vaccine against this particular H5N1 strain.
Bird flu, medically known as avian influenza, is a viral infection that primarily affects birds. Highly pathogenic avian influenza (HPAI) strains, including H5N1, can cause severe illness and extremely high mortality among infected poultry.
Since the first detection of bird flu in India in 2006, the country has reported more than 500 combined outbreaks involving H5N1 and H5N8 subtypes.
These outbreaks can have serious economic consequences. Infected birds may need to be culled to prevent further transmission. The 2006 outbreak alone resulted in estimated direct and indirect losses of Rs 2,200–3,000 crore.
The newly developed vaccine can help strengthen the country’s ability to prevent outbreaks and protect poultry populations against the H5N1 strain currently circulating in the country.
Also read: UK Reports Its First Human Case Of Bird Flu
The indigenous vaccine contains an inactive version of the virus that cannot replicate and infect. When administered, it exposes the chicken's immune system to viral components, just enough to allow it to recognise the virus and develop an immune response.
If the vaccinated bird encounters the actual virus later, its immune system can recognise it and respond more effectively.
The vaccine announcement comes just as fresh reports of bird flu infections in poultry have emerged.
In Tamil Nadu's Cuddalore district, H5N1 infections were confirmed following sudden deaths among chickens at poultry farms. More than 35,000 birds had died by November 13, prompting authorities to initiate containment and culling efforts.
Andhra Pradesh has also reported H5N1 infections in poultry, prompting restrictions and surveillance measures.
The indigenous vaccine is an important step in India's poultry disease-control efforts, but its introduction does not mean bird flu outbreaks will be prevented completely.
Its effectiveness depends on vaccination coverage, administration, monitoring of viral strains and compliance with farm biosecurity measures.
Also read: New Strain Of Bird Flu Detected In US, Here’s How You Can To Stay Protected
Although H5N1 primarily affects birds, the virus can occasionally cross the zoonotic barrier and infect humans, especially those who have long-term contact with infected birds, their secretions or contaminated environments.
Human infections can cause symptoms ranging from mild respiratory illness to severe pneumonia and, in some cases, death.
According to the World Health Organization (WHO), 1,003 human cases of H5N1 infection, including 479 deaths, had been reported across 25 countries since 2003, as cited in the Indian government's November 18 announcement.
Human infections, however, remain relatively uncommon and sustained human-to-human transmission has not been established.
People working with poultry should avoid handling sick or dead birds without protective equipment. Unusual bird deaths should be reported to veterinary authorities.
Credit: iStock
Lung cancer remains the leading cause of cancer deaths in the US, with 229,410 new cases expected this year, according to a annual report from the American Lung Association's (ALA).
The Association's ninth annual State of Lung Cancer report stated that although five-year survival has improved, low screening rates, delayed diagnosis and unequal access to treatment remain major challenges.
Harold Wimmer, President and CEO of the ALA, said, “the national five-year survival rate has increased significantly, from 18.1% to 31.0%, and screening rates have also continued to rise.”
However, he warned that progress has not reached all communities equally.
“Awareness is still low and challenges remain. We must continue to drive progress on lung cancer screening, comprehensive biomarker testing, clinical trials and effective treatments to help people live longer, fuller lives after a lung cancer diagnosis.”
Only 29.3% of lung cancer cases are diagnosed early. Rhode Island recorded the highest early diagnosis rate at 38%, while Hawaii had the lowest at 21.9%.
More concerning, 20.9% of patients received no treatment. The ALA identified potential barriers including lack of awareness, stigma, fatalism after diagnosis and treatment costs.
No-treatment rates ranged from 13.4% in Rhode Island to 36.7% in Nevada.
Annual low-dose CT scans can detect lung cancer early in people at high risk. Yet only 24.4% of eligible Americans underwent screening.
Massachusetts recorded the highest screening rate at 38.7%, while South Dakota had the lowest at 13.5%.
Other Key Findings
Smoking is a major risk factor. Others include radon gas, air pollution and secondhand smoke. The ALA recommends radon testing, reducing air pollution and stronger tobacco-control measures, including smoke-free laws and access to smoking cessation services.
Cleveland Clinic defines lung cancer as a malignant disease that happens when cells in the lung tissue grow out of control and form tumors. It is the leading cause of cancer deaths worldwide.
Lung cancer may cause no noticeable symptoms in its early stages. Symptoms can include persistent cough, coughing up blood, chest pain, unexplained weight loss, shortness of breath, recurrent chest infections and fatigue.
These symptoms should not be ignored. Early detection improves the chances of successful treatment, particularly before the cancer spreads.
Credit: iStock
Several antibiotics used to treat infections caused by E. coli and Klebsiella pneumoniae—bacteria linked to pneumonia, urinary tract and bloodstream infections—are showing low susceptibility in India, with resistance also reported to powerful drugs such as carbapenems, according to a new Indian Council of Medical Research (ICMR) report.
The newly released ICMR Antimicrobial Resistance Surveillance and Research Network (AMRSN) Annual Report 2025 assesses the distribution of bacterial pathogens and their susceptibility to different antibiotics.
The surveillance covers Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa, as well as Gram-positive bacteria such as Staphylococcus aureus and Enterococcus species.
For the first time, the report included data from 34 secondary-care hospitals, highlighting that antibiotic resistance is a concern beyond large, specialised hospitals.
The findings underscore the need for better diagnostics, responsible antibiotic use and stronger infection prevention.
"Antibiotic resistance is no longer a distant threat—it is affecting patients and families across India," Dr Neha Rastogi Panda, Senior Consultant, Infectious Diseases, Fortis Hospital, Gurugram, told HealthandMe.
Also read: Antimicrobial Resistance Could Contribute To 39 Million Deaths By 2050: WHO
The report highlighted several concerning resistance patterns across bacterial pathogens, including:
1. E. coli: Low susceptibility to cefotaxime and ceftazidime
The report showed that susceptibility of E. coli isolates to third-generation cephalosporins was low, with only 18.4% and 24.7% susceptible to cefotaxime and ceftazidime, respectively.
Low susceptibility was also observed among isolates from outpatient department (OPD) patients, suggesting that resistance to these antibiotics is widespread in the community and indicating a high prevalence of antibiotic-blocking enzymes.
2. K. pneumoniae: Low susceptibility to piperacillin-tazobactam and carbapenems
K. pneumoniae showed an alarmingly high resistance profile, with only 29.2% susceptible to piperacillin-tazobactam, 23–27% to third-generation cephalosporins, and only 35–40% to carbapenems.
Amikacin susceptibility was limited to 44.5%, while susceptibility to ceftazidime-avibactam was 37.7%. Tigecycline showed higher susceptibility, at 79.3%.
3. E. coli: Ceftriaxone susceptibility falls in secondary-care hospitals
Ceftriaxone susceptibility declined from 39.8% in Category I to 28.0% in Category II and 11.5% in Category III hospitals, indicating a high prevalence of resistance to third-generation cephalosporins even in smaller hospitals.
Meropenem susceptibility also declined across the three categories, from 80.3% to 77.5% and 67.1%, respectively.
4. Acinetobacter baumannii: High carbapenem resistance
A high prevalence of carbapenem resistance was observed among A. baumannii, with 91.1% of revived isolates exhibiting carbapenem resistance, highlighting a substantial therapeutic and infection-control challenge.
OXA-23 was the predominant carbapenemase determinant, with frequent detection of OXA-23 and NDM co-profiles.
5. Salmonella Typhi and Salmonella Paratyphi A: Very low ciprofloxacin susceptibility
Fluoroquinolone susceptibility was lowest among the antibiotics assessed for both pathogens. Ciprofloxacin susceptibility was observed in only 2.0% of S. Typhi isolates and 0.4% of S. Paratyphi A isolates.
Dr Rastogi Panda warned that every time an antibiotic is misused, it increases the risk of making future infections harder to treat.
She advised people to:
"Cancer patients, ICU patients, the elderly and those with weakened immunity are particularly vulnerable. Responsible antibiotic use, vaccination and good hand hygiene can save lives. Protect antibiotics today, so they protect us tomorrow," the expert said.
© $2026 Times Horizon Private Limited